Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 132

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 2
Chunk 132
---
 our average daily trading volume was approximately 1,183,339 shares and the intra-day sales prices per share of our common stock on the Nasdaq Capital Market ranged from $32.33 to $117.33. As of July 24, 2025, our officers, directors and principal stockholders beneficially owned approximately 21 percent of our common stock.

Our stock price can experience extreme price and volume fluctuations that are unrelated or disproportionate to our operating performance or prospects. Securities class action lawsuits are often instituted against companies following periods of stock market volatility. Such litigation is costly and diverts management’s attention from productive efforts.

Factors that may cause the price of our common stock to fluctuate rapidly and widely include:

•actual or anticipated variations in our operating results or changes to any public guidance we have provided;

•actual or anticipated timing and results of our clinical trials;

•actual or anticipated regulatory approvals of our product candidates;

•disputes or other developments relating to our intellectual property, including developments in generic-related litigation;

35

•changes in laws or regulations applicable to the pricing, availability of insurance reimbursement, or approved uses of our commercialized products, our product candidates or our competitors’ products;

•short-selling of our common stock, the publication of negative opinions about our business or other market manipulation activities that are intended to lower our stock price or increase its volatility;

•sales of a substantial number of shares of our stock in the public market, leading to reductions in its price;

•changes in estimates or recommendations by securities analysts or the failure of our performance to meet the published expectations of those analysts or public guidance we have provided;

•purchases of our common stock pursuant to our stock repurchase program (the “Stock Repurchase Program”) or changes to that program;

•general market and economic conditions;

•changes in the expected or actual timing of our competitors’ development programs and the approval of competing products;

•purchases or sales of our common stock by our officers, directors or stockholders;

•technological innovations by us, our collaborators or our competitors;

•conditions in the pharmaceutical industry, including the market valuations of companies similar to ours;

•additions or departures of key personnel;

•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; and

•additional financing activities.

Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.

The guidance we provide as to our